Bioavailability of medroxalol in man

Area of Science:

• Pharmacokinetics
• Drug formulation
• Clinical pharmacology

Background:

• Medroxalol is a beta-adrenergic blocking agent.
• Understanding medroxalol's absorption is crucial for effective therapeutic use.

Purpose of the Study:

• To evaluate the pharmacokinetic profile and absolute bioavailability of medroxalol.
• To compare the bioavailability of medroxalol administered as an oral solution versus a tablet formulation.

Main Methods:

• A randomized three-way crossover study was conducted in ten healthy male volunteers.
• Single oral doses (solution and tablet) and an intravenous dose of 100 mg medroxalol were administered.
• Plasma concentrations and urinary excretion were monitored to determine pharmacokinetic parameters.

Main Results:

• Mean terminal half-lives were similar across formulations (11.3-13.4 h).
• Absolute bioavailability was 54% for the solution and 38% for the tablet.
• Relative bioavailability of the tablet compared to the solution was 71%.

Conclusions:

• The oral solution formulation of medroxalol demonstrated significantly higher bioavailability than the preliminary tablet formulation.
• Differences in absorption may be attributed to formulation characteristics.
• Further development may be needed to optimize medroxalol tablet bioavailability.